Home » Stocks » NXTC

NextCure, Inc. (NXTC)

Stock Price: $13.60 USD 1.00 (7.94%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $13.50 -0.10 (-0.74%) Jan 22, 5:10 PM
Market Cap 374.72M
Revenue (ttm) 24.38M
Net Income (ttm) -32.07M
Shares Out 27.55M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $13.60
Previous Close $12.60
Change ($) 1.00
Change (%) 7.94%
Day's Open 12.60
Day's Range 12.50 - 14.04
Day's Volume 419,988
52-Week Range 8.15 - 49.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immun...

The Motley Fool - 3 weeks ago

These companies are eager to say good riddance to the year that was.

Other stocks mentioned: AMRN, ICPT, IVR, NGL, PBF, SNDL, TCDA, TELL, WPG
Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextCure, Inc. (“NextCu...

GlobeNewsWire - 1 month ago

BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immun...

Zacks Investment Research - 1 month ago

NextCure (NXTC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC).   Such investors are advised ...

GlobeNewsWire - 2 months ago

BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immun...

PRNewsWire - 2 months ago

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities c...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 19, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) betwee...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextC...

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class ...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 17, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Next...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 16, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Next...

PRNewsWire - 2 months ago

NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 a...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 13, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Next...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against NextC...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between...

GlobeNewsWire - 2 months ago

BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immun...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - October 31, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between ...

PRNewsWire - 2 months ago

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 a...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 23, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between...

PRNewsWire - 3 months ago

LOS ANGELES, Oct. 22, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action ...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 17, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between ...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between ...

PRNewsWire - 3 months ago

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 an...

PRNewsWire - 3 months ago

BENSALEM, Pa., Oct. 8, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action file...

PRNewsWire - 3 months ago

LOS ANGELES, Oct. 6, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise ac...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NextCure, Inc. (NASDAQ: NXTC): (1) between November 5, 2019 and July 14, 2...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 2, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the secur...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure” or "the Company") (NASDAQ:NXTC) a...

Business Wire - 3 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Deadline in the Class Action Against NextCure,Inc.(NXTC)on Behalf ...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 1, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NextCure, Inc. ("NextCure" or the "Company") (NASDAQ...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - September 30, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NextCure, Inc. ("NextCure" ...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action of a Securities Class Action Lawsuit Against NextCure, In...

PRNewsWire - 3 months ago

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action t...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that: (i) purchas...

Business Wire - 4 months ago

SAN DIEGO & BELTSVILLE, Mass.--(BUSINESS WIRE)---- $NXTC #ClassAction--Shareholder rights law firm Robbins LLP announces that an investor of NextCure, Inc. (NASDAQ: NXTC) filed a class action ...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #NXTC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against NextCure, Inc.

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)-- #CLASSACTION--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Investors

Business Wire - 4 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NextCure, Inc. (NXTC) Inves...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of NextCure Inc. ("...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of NextCure Inc. ("...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NextCure, Inc. (NASDAQ...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $NXTC #classaction--The Law Offices of Frank R. Cruz announces an investigation of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) on behalf of inv...

Business Wire - 4 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $NXTC #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NextCure, Inc. (NXTC) on Behalf of Investors

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)----Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action...

About NXTC

NextCure, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and researc... [Read more...]

Industry
Biotechnology
IPO Date
May 9, 2019
CEO
Michael S. Richman
Employees
69
Stock Exchange
NASDAQ
Ticker Symbol
NXTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for NextCure stock is "Buy." The 12-month stock price forecast is 23.33, which is an increase of 71.54% from the latest price.

Price Target
$23.33
(71.54% upside)
Analyst Consensus: Buy